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Abstract
Background: Mycobacterium avium subspecies paratuberculosis (MAP) is an infective agent found in ruminants and
milk products, which has been suggested to increase the risk of gastrointestinal inflammation in genetically
susceptible hosts. It is hypothesized that lactase persistence facilitates exposure to such milk products increasing
the likelihood of adverse outcomes. Individuals either homozygous or heterozygous for the T allele of DNA variant,
rs4988235, located 14kb upstream from the LCT locus, are associated with having lactase persistence.
The aim of this study was to determine whether lactase persistence as evident by the T allele of rs4988235 is asso-
ciated with Crohn’s Disease (CD) in a New Zealand population.
Findings: Individuals homozygous for the T allele (T/T genotype) showed a significantly increased risk of having
CD as compared with those homozygous for the C allele (OR = 1.61, 95% CI = 1.03-2.51). Additionally, a significant
increase in the frequency of the T allele was observed in CD patients (OR = 1.30, 95% CI = 1.05-1.61, p = 0.013),
indicating that the T allele encoding lactase persistence was associated with an increased risk of CD.
Conclusions: Our findings indicate that lactase persistence as evident by the presence of the T allele of rs4988235
is associated with risk of CD in this New Zealand Caucasian population.
Background
Crohn’s Disease (CD) is a form of inflammatory bowel
disease of both genetic and environmental aetiology.
Somewhat controversially Mycobacterium avium subsp.
Paratuberculosis (MAP) exposure has resurfaced within
the literature as a potential environmental variant that
may be implicated in the development of CD [1]. MAP
is an infective agent frequently found in ruminants such
as cows and sheep that results in Johne’sd i s e a s e ,a n
inflammatory bowel condition similar to that experi-
enced by humans with CD [2]. MAP is secreted into the
milk of infected ruminants [3] and is delivered to
humans via the consumption of milk products [4] due
to its reported resistance to commercial pasteurisation
methods [5,6].
One of the most important factors that may influence
the amount of milk consumed, and hence exposure to
MAP in humans relates to the presence of Lactase-
Phlorizin Hydrolase (lactase) in the small intestinal
mucosa. Lactase is the enzyme required to hydrolyse
lactose, the sugar found in milk products, into its con-
stituent galactose and glucose [7]. Infants are born with
the ability to digest lactose, but for the majority of the
world’s population this declines with age, a phenomenon
known as lactase non persistence. However, lactase per-
sistence is highly prevalent in descendants from popula-
tions with a rich pastoralist heritage [8]. Greater than
70% of individuals of white European heritage are
reportedly lactose persistent compared to less than 40%
throughout individuals from Asian countries [9].
Ennatah et al [10] identified a DNA variant, rs4988235
(c.1993+327 C > T, previously termed C/T-13910); 14kb
upstream from the LCT locus that demonstrated com-
plete agreement with clinically identified lactase non
persistence in a Finnish population. LCT is a gene
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the hydrolysis of lactose. Homozygotes for the C allele
of rs4988235 were found to be lactase-non persistent,
whilst those heterozygous or homozygous for the T
allele were determined to be lactase persistent. This
finding has been replicated in several other European
populations [11,12] and support for the functionality
of this DNA variant has been demonstrated in vitro
[13]. Thus the C/C genotype for rs4988235 is now a
widely accepted marker of adult-type hypolactasia in
Europeans.
Evaluating the association of lactase persistence with
CD as a key factor influencing exposure to MAP via the
consumption of milk products is particularly important
in New Zealand, a country with one of the highest inci-
dences of CD in the Western world at 16.5/100,000 per
year [14] coupled with the highest herd prevalence esti-
mate of Johne’s disease at 60% [5].
The aim of this study was to determine whether lactase
p e r s i s t e n c ea se v i d e n tb yt h ep r e s e n c eo ft h eTa l l e l eo f
rs4988235 is associated with CD in a New Zealand
population.
Methods
Samples
T h eA u c k l a n dC DP r o j e c ti sap o p u l a t i o n - b a s e ds t u d y
of genetic and environmental determinants of CD
aetiology. CD patients were recruited between May
2005 and April 2007 through local doctors and sur-
geries in Auckland, New Zealand, and also other North
Island centres, by media campaigns, e.g. local newspaper
and television. Controls were recruited by the same
means, and also recruited from non-affected family
members and friends of CD patients. Participants con-
sented to collection of peripheral blood for DNA
extraction and genotyping.
A total of 945 subjects (333 CD patients and 612 con-
trols) consented to take part. The cases in this study are
a subset of the Caucasian participants of the Auckland
CD Project. Their gastroenterologists were approached,
clinical records scrutinised to confirm diagnosis, and
CD was defined using standard diagnostic criteria [15].
Cases were phenotyped according to the Montreal Clas-
sification systems, allowing genotype-phenotype analysis
to be performed. Phenotypic information was available
for 323 CD patients. All participants included in this
study were of self-reported European ancestry (subjects
who self-reported having any Maori or other non-
Caucasian ancestry are not included in the dataset).
The study was conducted under ethical protocol
MEC/04/12/011, authorised through the New Zealand
Multi-Region Human Ethics Committee. All study sub-
jects gave informed consent.
DNA was extracted from blood samples or buccal
swabs using Qiagen’s DNA extraction kit (Qiagen,
Valencia, CA, USA) and following the manufacturer’s
instructions.
Genotyping
Genotyping of rs4988235 was performed using the ABI
TaqMan MGB diallelic discrimination system with for-
ward and reverse primer sequences 5’-CTG CGC TGG
CAA TAC AGA TAA G-3’ and 5’AAA TGC AAC CTA
AGG AGG AGA GTT C-3’ respectively and VIC– ATA
ATG TAG TCC CTG GCC T and FAM–ATA ATG
TAG CCC CTG GC probes (Applied Biosystems, Mel-
bourne, Australia). The reactions were prepared using
2× TaqMan Universal Master Mix, 40× SNP Genotyping
A s s a yM i x ,D N a s e - f r e ew a t e r ,a n d1 0n gg e n o m i cD N A
in a final volume of 5 ul per reaction. The PCR amplifi-
cation was performed using the ABI Prism 7900 HT
sequence-detector machine under the following condi-
tions: 50°C for 2 minutes, 10 min 95°C enzyme activa-
tion followed by 40 cycles at 95°C for 15 sec and 60°C
for 1 min (annealing/extension).
To reduce the possibility of genotyping error, genotyp-
ing was repeated utilising different primers (5’-CTC TGC
GCT GGC AAT ACA G and 5’-AAA TGC AAC CTA
AGG AGG AGA) and probes (VIC-ATA AGA TAA TGT
AGC CCC TGG C and FAM- ATA AGA TAA TGT
AGT CCC TGG C) (Applied Biosystems, Melbourne, Aus-
tralia) under the following conditions: 60°C for 1 minute,
95°C for 10 minutes, followed by 55 cycles of 92°C for 15 s
and 60°C for 1 minute and 60°C for 1 minute.
The allelic discrimination results for both sets of gen-
otyping were determined after the amplification by per-
forming an endpoint read.
Assays were optimized in 24 samples consisting of 20
reference Centre d’Etude du Polymorphisme Humain
(CEPH) samples and 4 blanks. All sample plates con-
tained cases, controls, blanks, CEPH and duplicate sam-
ples. Quality control measures included independent
double genotyping, blind to sample identity and blind to
the other caller, and comparison of our CEPH genotypes
to those in the HapMap http://www.hapmap.org.
Statistical analysis
The allelic trend test [16] was used to compare frequen-
cies between case and control alleles. An exact test was
used to test for departures from Hardy-Weinberg equili-
brium (HWE) in the case and the control samples [17].
Lactase persistence was defined as having genotypes C/
T and T/T of rs4988325 whilst C/C was defined as lac-
tase non-persistence.
Genotypic analysis was carried out and the allelic odds
ratio with confidence interval was calculated to test the
effect of the T allele on CD risk.
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(Ihaka and Gentleman, 1996) were used for statistical
analyses.
Results
The genotypes did not meet Hardy-Weinberg equili-
brium (HWE) for both the cases and controls. To ensure
genotyping errors did not exist in the data, genotyping
was repeated using an alternative primer and probe set
and the genotypes were confirmed to be correct. Also,
the minor allele frequency was 0.273 which is similar to
the HapMap CEU population frequency of 0.274. Devia-
tions from HWE may have resulted by chance, as a result
of population admixture or perhaps the rs4988235 SNP
is associated with a currently unknown factor in controls.
For rs4988235, the T/T genotype showed a signifi-
cantly increased risk of having CD as compared with
the C/C genotype (OR = 1.61, 95% CI = 1.03-2.51) how-
ever, no significant difference was found between C/T
and C/C. Additionally, a significant increase in the fre-
quency of the T allele was observed in CD patients (OR
= 1.30, 95% CI = 1.05-1.61, p = 0.013), indicating that
the T allele encoding lactase persistence was associated
with risk of CD (Table 1).
Genotype-phenotype analysis: of 323 cases, 88 (28.4%)
had relatives with IBD, 98 (31.6%) had undergone a
bowel resection, 44 (14.2%) had extra-intestinal manifes-
tations of CD occurring and 112 (46.9%) smoked at
diagnosis (Table 2).
Individuals carrying the T allele of rs4988235 had an
increased probability of developing CD that was diag-
nosed between 17 and 40 years (OR = 1.36, 95% CI =
1.05-1.76, p = 0.021); and a significantly increased risk
of developing ileal CD (OR = 1.50, 95% CI = 1.05-2.15,
p = 0.032) or CD of an inflammatory nature (OR =
1.36, 95% CI = 1.02-1.82, p = 0.039). In addition, a sig-
nificantly increased risk of having other relatives with
IBD and of undergoing bowel resection was observed in
individuals with the T allele of rs4988235 (OR = 1.71,
95% CI = 1.17-2.51, p = 0.006 and OR = 1.47, 95% CI =
1.03-2.10, p = 0.033 respectively).
Discussion
Results from this study suggest that genetic adult-type
lactase persistence as evident by the T allele of
rs4988235 may increase the risk of developing CD in
this New Zealand population.
Our findings are in agreement with Juste et al [18],
who reported an increased frequency of the T allele of
rs4988235 in CD patients (61.9%) compared with con-
trols (47.1%, p = 0.0275). Similarly a highly significant
correlation between incidence of CD and lactase persis-
tence (r = -0.655, p = 0.0017) was reported in an obser-
vational study encompassing data from 20 countries
[19], whilst Shrier et al [20] reported a reduction in CD
risk with increasing prevalence of lactase non-persis-
tence in a review of global population data.
Conversely, Büning et al [21] failed to find an associa-
tion between the C/C genotype of rs4988235 and the
pathogenesis of CD in a German case-control study of
166 CD patients and 187 healthy controls. This discre-
pancy may relate to the smaller sample size of this study;
however evaluation of this phenomenon on a regional
basis, taking into consideration adult lactase status, dairy
food consumption, and degree and management of MAP
infection within ruminant populations may provide evi-
dence to ensure that a consensus can be reached regard-
ing the role of lactase persistence and MAP exposure in
the aetiology of CD.
The finding that lactase persistence was associated
with an increased risk of having a relative with inflam-
matory bowel disease may reflect the autosomal domi-
nant nature of lactase persistence, whilst the increased
Table 1 Genotype and allele count frequencies for
rs4988235 in CD patients and in controls
Genotype Allele CD
N (%)
Control
N(%)
OR (95%CI) p
C/C 32 (9.6) 82 (13.4) 1.00 0.065
C/T 118 (35.4) 238 (38.9) 1.27 (0.80-2.02)
T/T 183 (55.0) 292 (47.7) 1.61 (1.03-2.51)
Z = 2.34, p < Z 0.009*
T 484 (72.7) 822 (67.2) 1.30 (1.05-1.61) 0.013
C 182 (27.3) 402 (32.8) 1.00
*Cochran-Armitage Trend Test
Table 2 Summary of clinical data in subgroups of CD
patients with a T allele for rs4988235
N (%) OR (95% CI) p
Age at first diagnosis
0-16 years 30 (10.6) 0.98 (0.55-1.75) 1.00
17-40 years 203 (71.5) 1.36 (1.05-1.76) 0.021
> 40 years 51 (18.0) 1.56 (0.96-2.53) 0.087
CD location
Ileal 97 (36.5) 1.50 (1.05-2.15) 0.032
Colonic 86 (32.3) 1.26 (0.88-1.81) 0.245
Ileocolonic 83 (31.2) 1.25 (0.86-1.81) 0.273
CD Behaviour
Inflammatory 152 (57.6) 1.36 (1.02-1.82) 0.039
Stricturing 81 (30.7) 1.27 (0.87-1.85) 0.233
Penetrating 31 (11.7) 1.41 (0.77-2.57) 0.315
Relative with IBD 88 (28.4) 1.71 (1.17-2.51) 0.006
Bowel resection 98 (31.6) 1.47 (1.03-2.10) 0.033
Extra Intestinal
Manifestations
44 (14.2) 1.38 (0.84-2.28) 0.228
Smoker at diagnosis CD: 112 (46.9)
Control: 130 (31.7)
1.04 (0.69-1.56) 0.918
*IBD - Inflammatory Bowel Disease
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correspond with the onset of hypolactasia that typically
occurs in adulthood in susceptible individuals. The T
allele for rs4988235 was also associated with an
increased risk of inflammation, having an ileal CD loca-
tion and bowel resection amongst CD cases. This was
an unexpected finding and warrants further investigation
to conclusively determine whether lactase persistence
may influence the phenotypic expression of CD.
As associations between MAP and inflammatory
bowel disease have largely been limited to individuals
with CD, this study did not evaluate lactase persistence
in the ulcerative colitis context. However, the inclusion
of this clinical population in future research may pro-
vide further insights into the potential association
between lactase persistence and inflammatory bowel
disease.
Whether lactase persistence is an independent risk
factor for CD or merely a marker of the likelihood of
exposure to the MAP pathogen, found predominantly in
milk products, is beyond the scope of this particular
study. However epidemiological evidence is conflicting,
indicating an urgent need for further, well controlled
dietary and genetic case-control studies to distinguish
between these two hypotheses.
I nJ a p a n ,S h o d ae ta l[ 2 2 ]r e p o r t e dt h a ti n c i d e n c eo f
CD was strongly correlated with consumption of milk
protein and Shrier et al [18] identified a trend with esti-
mated yearly per capita dairy food consumption and
increased risk of CD. In contrast Abubakar et al [23]
reported that consumption of pasteurized milk was asso-
ciated with a decreased risk of CD in a case-control
study of 218 individuals with CD in England.
Recent advances in technology have ensured that the
presence of MAP in vivo is more accurately detected
[24]. These advances have contributed to the resurgence
of the MAP and CD hypothesis. Viable MAP was recently
identified in the peripheral blood of a high proportion of
individuals with CD, with only MAP DNA isolated in a
small proportion of controls [25]. This may reflect differ-
ent physiological responses to the pathogen between
cases and controls. These findings were supported locally
in a New Zealand study, utilising a larger cohort of 361
CD patients and 200 controls. In this study MAP DNA in
peripheral blood was found to be over-represented in CD
patients in comparison to controls [26].
The Zoonotic potential of MAP was discussed in a
review by Grant [5], who reported that hypotheses sug-
gesting a causal role for MAP in the pathogenesis of CD
were plausible, however insufficient available evidence
can either prove or disprove this idea at present.
Results from this exploratory study do not prove that
MAP exposure is responsible for the development of
CD; or that milk products increase risk of the
development of CD. However our findings indicate that
there may be a complex interaction between exposure
to this infectious agent as a consequence of an evolu-
tionary adaptation to ensure tolerance to the milk pro-
ducts that may serve as the medium for its delivery to
humans. As the worldwide incidence of CD is rapidly
increasing, [27-29], there is an urgent need to determine
whether our findings can be replicated in larger popula-
tions. If so, efforts to eradicate MAP through animal
vaccination and greater prevention of its contamination
into the food supply should become key public health
priorities.
Conclusion
Following a case-control evaluation of rs4988235 in a
New Zealand CD population, we found that lactase per-
sistence as evident by the presence of a T allele was
associated with increased CD risk. This finding may
relate to the increased exposure to dairy products in
individuals with lactase persistence, a food group that
has been implicated in the aetiology of CD due to the
presence of MAP species in milk. Further research is
required to substantiate our findings and to conclusively
determine the nature of the observed association
between lactase persistence and CD.
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